Overdose profiles of new antipsychotic agents

International Journal of Neuropsychopharmacology

Volumn 3, Issue 1, 2000, Pages 51-54

  Capel, Margred M ^a   Colbridge, Mark G ^b   Henry, John A ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clozapine; Olanzapine; Risperidone; Sulpiride; Toxicity

Indexed keywords

BUTYROPHENONE DERIVATIVE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE; SULPIRIDE;

ADOLESCENT; ADULT; AGITATION; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; DYSTONIA; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; MALE; POISON CENTER; PRIORITY JOURNAL; PSYCHOSIS; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0034081884     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145700001760     Document Type: Article

References (12)

1. Acri AA, Henretig FM (1998). Effects of risperidone in overdose. American Journal of Emergency Medicine 16, 498-501.
2. British National Formulary (1997). British Medical Association and Royal Pharmaceutical Society of Great Britain. No. 33, March 1977.
3. Buckley N, McManus, P (1998). Fatal toxicity of drugs used in the treatment of psychotic illnesses. British Journal of Psychiatry 172, 461-463.
4. Cohen R, Hart J (1995). In: Student Psychiatry Today, A Comprehensive Textbook (2nd edn) (pp. 105-248). Oxford: Butterworth Heinemann.
5. Fletcher L (1996). Facing up to the facts of mental illness. From phantoms to physiology. TRP3 Neuroscience, Brain Function and Mental Health. Research and Funding News from the Wellcome Trust 9, 24.
6. Fogel J, Diaz J (1998). Olanzapine overdose. Annals of Emergency Medicine 32, 275-276.
7. Hobbs WR, Rall TW, Verdoorn TA (1996). Management of insomnia. In: Hardman J, Limbird L, Molinoff PB, Ruddon RW, Goodman LS, Gilman A (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th edn) (pp. 383-436). New York: McGraw Hill.
8. Hale A (1997). Drug focus, olanzapine. British Journal of Hospital Medicine 58, 442-445.
9. Hasan S, Buckley P (1998). Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. American Journal of Psychiatry 155, 1113-1114.
10. Perkins DO, Lieberman JA (1998). Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. Clinical case conference. American Journal of Psychiatry 155, 272-278.
11. Reus V (1997). Olanzapine: a novel atypical neuroleptic agent. Lancet 349, 1264-1265.
12. Thomas CS, Lewis S (1998). Which atypical antipsychotic? British Journal of Psychiatry 72, 106-109.